Key result
Lysophosphatidic acid drives oxidized LDL-induced platelet and endothelial activation in human atherosclerotic lesions.
Oxidized low density lipoprotein (LDL) is a key factor in the pathogenesis of atherosclerosis and its thrombotic complications, such as stroke and myocardial infarction. It activates endothelial cells and platelets through mechanisms that are largely unknown. Here, we show that lysophosphatidic acid (LPA) was formed during mild oxidation of LDL and was the active compound in mildly oxidized LDL and minimally modified LDL, initiating platelet activation and stimulating endothelial cell stress-fiber and gap formation. Antagonists of the LPA receptor prevented platelet and endothelial cell activation by mildly oxidized LDL. We also found that LPA accumulated in and was the primary platelet-activating lipid of atherosclerotic plaques. Notably, the amount of LPA within the human carotid atherosclerotic lesion was highest in the lipid-rich core, the region most thrombogenic and most prone to rupture. Given the potent biological activity of LPA on platelets and on cells of the vessel wall, our study identifies LPA as an atherothrombogenic molecule and suggests a possible strategy to prevent and treat atherosclerosis and cardiocerebrovascular diseases.
No takes yet. Share an insight, caveat, or question.
Siess et al. (1999) studied Atherosclerosis and thrombotic complications. Lysophosphatidic acid (LPA) and mildly oxidized LDL was evaluated on Platelet and endothelial cell activation. Lysophosphatidic acid was identified as the active compound in mildly oxidized LDL responsible for initiating platelet and endothelial cell activation, accumulating in human atherosclerotic lesions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: